Slingshot Insights

Additional Relevant Details On January 7, 2016 Progenics announced that it had begun enrollment for is pivotal Phase 3 Study of PSMA targeted imaging Agent 1404 for prostate cancer. The study is expected to enroll around 450 patients with low-grade prostate cancer. The primary endpoint is whether 1404 correctly identifies whether or not patients have clinically significant prostate cancer. Completion of enrollment of the patients is expected in early 2016.

http://ir.progenics....

Additional Relevant Details we’ve continued to advance our clinical development strategy for our imaging agents 1404 and PyL. 1404 is focused on early monitoring applications such as enabling active surveillance. Our ongoing pivotal Phase 3 trial is progressing as planned and we remain on track to conduct an interim analysis of the data to assess futility and evaluate the need for a sample size re-estimation in the second of 2016.

http://seekingalpha....

Additional Relevant Details "Phase 3 Study Enrollment of PSMA-Targeted SPECT/CT Imaging Agent 1404 Ongoing"

http://ir.progenics....

Additional Relevant Details Update on Nov 7 2016: Enrollment in Pivotal Phase 3 Study of 1404 is Ongoing. The study will enroll up to 450 patients with newly-diagnosed or low-grade prostate cancer who are candidates for active surveillance. Progenics plans for an interim analysis by the end of this year, to assess futility and evaluate the need for a sample size re-estimation, remain unchanged.

http://ir.progenics....

Catalyst

Do you think this event is important to the companies below? How will it affect their stock price?

Additional Information

Slingshot Insights Explained